Rapid and dramatic radiographic and clinical response to an ALK inhibitor (Crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer Journal Article


Authors: Ou, S. H. I.; Bazhenova, L.; Camidge, D. R.; Solomon, B. J.; Herman, J.; Kain, T.; Bang, Y. J.; Kwak, E. L.; Shaw, A. T.; Salgia, R.; Maki, R. G.; Clark, J. W.; Wilner, K. D.; Iafrate, A. J.
Article Title: Rapid and dramatic radiographic and clinical response to an ALK inhibitor (Crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer
Keywords: adult; human tissue; treatment response; gene translocation; human cell; case report; bevacizumab; cisplatin; erlotinib; positron emission tomography; antineoplastic agent; computer assisted tomography; lung non small cell cancer; epidermal growth factor receptor; docetaxel; liver metastasis; lung adenocarcinoma; fluorescence in situ hybridization; fluorodeoxyglucose f 18; brain metastasis; cytokeratin 20; thorax radiography; stereotactic radiosurgery; cytokeratin 7; k ras protein; pemetrexed; thyroid transcription factor 1; anaplastic lymphoma kinase; 3 [1 (2,6 dichloro 3 fluorophenyl)ethoxy] 5 [1 (4 piperidinyl) 1h pyrazol 4 yl] 2 pyridinylamine; diagnostic test accuracy study; chinese; endobronchial ultrasonography
Journal Title: Journal of Thoracic Oncology
Volume: 5
Issue: 12
ISSN: 1556-0864
Publisher: Elsevier Inc.  
Date Published: 2010-12-01
Start Page: 2044
End Page: 2046
Language: English
DOI: 10.1097/JTO.0b013e318200f9ff
PROVIDER: scopus
PUBMED: 21102269
DOI/URL:
Notes: --- - "Export Date: 20 April 2011" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Maki
    238 Maki